Obducat AB (publ) meddelade den 18 december 2024 att Obducats dotterbolag Obducat Europe GmbH har er...
Mendus has reported positive top-line data for its Phase I ALISON trial, which is evaluating lead of...
Redeye comments on a new additional supplier of Terbinafine that already holds an EU certificate of ...
SEK 185m order from Swedish Space Corporation on Ovzon-3 The full value will be paid in January 2025...
Titania meddelade den 17 december år 2024 att bolaget har tecknat ett avtal om förvärv av fastighete...
On December 17th, STENOCARE announced that the company has received approval for a new product in De...
Alisa Bank issued a profit warning for 2024, lowering expectations for total income and profitabilit...
SRV’s 2025 will still be driven by non-residential volumes while we expect that the residential pick...
Today (16 December), Elanders announced that it has implemented structural measures regarding its ro...
Redeye is positive to the news regarding the support from a new law in New York state for insurance ...
Surprising Q4 PW and CEO resignation, but likely two isolated events Volatile systems business behin...
Today, Medivir announced its application to start a phase II study in liver cancer was approved by t...
Addlife ökade omsättningen med 1% (3% organiskt) till 2 344 MSEK under tredje kvartalet, jämfört med...
Redeye sees encouraging news from Dignitana supporting insurance coverage from private health insure...
Redeye leaves a short comment on Stille following the company's announcement that the CEO will resig...
Tethys Oil har under hösten fått ett bud på 58,70 kr per aktie som ligger i princip mitt i intervall...
Verve Group is emerging as a strong adtech player, with particular strength in mobile and growing po...
Redeye returns with an updated view of Saniona following the Q3 report and the transformative licens...
Biovica records another quarter of modest quarterly IVD test sales growth of 50-55% (compared with t...
Redeye takes a positive stance towards Hanza's acquisition of Leden.
